VMI
STML

VHCP Management II’s Stemline Therapeutics, Inc. STML Stock Holding History

VHCP Management II’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-228,130
Closed -$1.95M – 22
2017
Q1 		$1.95M Sell
228,130
-87,850
-28% -$801K 0.8% 14
2016
Q4 		$3.38M Hold
315,980
– – 1.62% 13
2016
Q3 		$3.42M Hold
315,980
– – 1.76% 15
2016
Q2 		$2.14M Hold
315,980
– – 1.29% 17
2016
Q1 		$1.47M Hold
315,980
– – 0.97% 19
2015
Q4 		$1.99M Buy
+315,980
New +$2.56M 1.64% 15

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VHCP Management II's STML Position: Q2 2017 in Review

VHCP Management II sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 228,130 shares — an estimated $1.95M sold.

VHCP Management II first reported a position in STML in Q4 2015 and held it in 6 quarters. The position peaked at $3.42M in Q3 2016. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

  • VHCP Management II reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • VHCP Management II sold 228,130 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $1.95M.
  • VHCP Management II first reported a position in Stemline Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
  • VHCP Management II's Stemline Therapeutics, Inc. position peaked at $3.42M in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on VHCP Management II's 13F filing for Q2 2017, filed 11 Aug 2017.